Streetbeat News

MURA

Mural Oncology plc

https://www.muraloncology.com

Industry

Biotechnology

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.

Open

3.80

Mkt cap

62M

Volume

94K

High

3.80

P/E Ratio

-0.40

52-wk high

6.25

Low

3.59

Div yield

N/A

52-wk low

2.88

Mural Oncology's ARTISTRY-1 clinical trial results for Nemvaleukin show promising antitumor activity, especially in platinum-resistant ovarian cancer, as published in the Journal for ImmunoTherapy of Cancer.

Portfolio Pulse from

November 20, 2024 | 9:30 pm

Mural Oncology plc (Nasdaq: MURA) will participate in two upcoming investor conferences, highlighting its focus on developing novel cytokine therapies for cancer treatment.

Portfolio Pulse from

November 11, 2024 | 12:15 pm

HC Wainwright & Co. has initiated coverage on Mural Oncology with a Buy rating and set a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 10:58 am

Top Wall Street analysts initiated coverage on several companies, including Tandem Diabetes Care, Mural Oncology, ASP Isotopes, Curbline Properties, and MINISO Group. The ratings and price targets varied, with some stocks experiencing price changes following the announcements.

Portfolio Pulse from Avi Kapoor

October 04, 2024 | 1:18 pm

Mural Oncology shares surged after Raymond James initiated coverage with a Strong Buy rating and set an $18 price target.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 12:22 pm

Several healthcare stocks experienced significant price movements in Friday's pre-market session. Mural Oncology, Universe Pharmaceuticals, Biodesix, Allakos, SCWorx, and aTyr Pharma saw notable gains, while Avinger, Renovaro, Sage Therapeutics, Chromocell Therapeutics, Reshape Lifesciences, and BioCardia experienced declines.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 12:07 pm

Raymond James has initiated coverage on Mural Oncology with a Strong Buy rating and set a price target of $18, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 11:52 am

Mural Oncology is set to host a Virtual Investor Day to discuss new clinical insights into their late-stage trials of nemvaleukin, with key data readouts expected in 2025. An IND submission for their IL-18 program is planned for Q4 2025.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 11:20 am

Workday, Inc. (NASDAQ:WDAY) shares surged 11.9% in pre-market trading after reporting better-than-expected Q2 financial results, with revenue of $2.08 billion and adjusted earnings of $1.75 per share. Several other stocks also showed significant pre-market movements, including Sequans Communications S.A. (NYSE:SQNS) and Red Robin Gourmet Burgers, Inc. (NASDAQ:RRGB).

Portfolio Pulse from Avi Kapoor

August 23, 2024 | 10:53 am

Mural Oncology has reaffirmed its guidance that its cash and equivalents are expected to fund its operations into Q4 of 2025. Management also forecasts lower operating expenses in 2025 compared to 2024 due to the timing of clinical trial expenses.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:22 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.